FreeTheAI

Pulse Biosciences Partners With Clayman Thyroid Center for System Rollout and Clinical Trials

MixedMedium impact
PLSE$48.54 −7.45%

Pulse Biosciences, Inc. (NASDAQ:PLSE) has entered into a commercial and clinical agreement with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. Under the commercial arrangement, the center will use the company's nPulse Vybrance Percutaneous Electrode System to treat patients with symptomatic benign thyroid nodules. The center becomes the sole provider offering nPulse technology in the Tampa Bay region.

The agreement also includes a clinical collaboration to collect real-world patient outcomes and conduct clinical studies on Nanosecond Pulsed Field Ablation energy. Pulse Biosciences aims to build a broader body of evidence for its non-thermal ablation procedure, which uses electrical pulses rather than heat to remove targeted cells while protecting surrounding nerves and vessels. Patients receiving the treatment avoid open surgery and return home the same day.

Investors will be monitoring patient adoption rates at high-volume medical centers and incoming study results as Pulse Biosciences expands commercial access. Despite the strategic partnership announcement, shares of Pulse Biosciences, Inc. fell 7.45% to $48.54 in recent trading.

Key points

  • Pulse Biosciences partnered with the Clayman Thyroid Center in Tampa, Florida, for commercial deployment and clinical studies of its Vybrance system.
  • The Clayman Thyroid Center is currently the sole site in the Tampa Bay area delivering nPulse technology for symptomatic benign thyroid nodules.
  • The clinical initiative will gather real-world patient outcome data and conduct studies evaluating non-thermal nanosecond pulsed field ablation energy.
  • Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) traded down 7.45% to $48.54 following the announcement.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is the partnership between Pulse Biosciences and Clayman Thyroid Center?

The agreement covers commercial treatment of benign thyroid nodules using the nPulse Vybrance System and clinical collaboration to study real-world outcomes of nanosecond pulsed field ablation technology.

How does the nPulse Vybrance system work?

The system delivers ultra-short electrical energy bursts under ultrasound guidance to clear cells non-thermally. This spares surrounding nerves and vessels, allowing patients to go home the same day and avoid surgery.

Where is the Vybrance system currently available in Tampa Bay?

The Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida, is the only facility in the Tampa Bay area offering the nPulse Vybrance technology.